Biotech Values

[exwannabe]

Those two patients' status are quite easily explained - I know many people think that's cherry picking, I thought that too initially without seeing full dataset if you look back my old postings on this subject, I changed my position gradually with more data coming in - they were the oldest, and had lowest 6MWT around 250m at entry, which are major predicting factors to becoming non-ambulatory quickly, and they did.

If it is that simple, why not avoid the issue in the trial design?

No horse in this SRPT debate, but this exact argument seams weak.